Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Outcomes, health costs and use of antiplatelet agents in 7,082 patients admitted for an acute coronary syndrome occurring in a large community setting.

Maggioni AP, Rossi E, Cinconze E, Roggeri DP, Roggeri A, Fabbri G, De Rosa M; ARNO Cardiovascular Observatory.

Cardiovasc Drugs Ther. 2013 Aug;27(4):333-40. doi: 10.1007/s10557-013-6455-z.

PMID:
23519685
[PubMed - indexed for MEDLINE]
2.

The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).

Cheng CI, Chen CP, Kuan PL, Lei MH, Liau CS, Ueng KC, Wu CJ, Lai WT.

Clin Cardiol. 2010 Jun;33(6):E40-8. doi: 10.1002/clc.20730.

PMID:
20552592
[PubMed - indexed for MEDLINE]
3.

Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects.

Maggioni AP, Rossi E, Cinconze E, De Rosa M; on behalf of ARNO Cardiovascular Observatory*.

Eur J Prev Cardiol. 2013 Mar 28. [Epub ahead of print]

PMID:
23539716
[PubMed - as supplied by publisher]
4.

Clinical outcomes, health resource use, and cost in patients with early versus late dual or triple anti-platelet treatment for acute coronary syndrome.

Friedman H, Mollon P, Lian J, Navaratnam P.

Am J Cardiovasc Drugs. 2013 Aug;13(4):273-83. doi: 10.1007/s40256-013-0026-3.

PMID:
23728829
[PubMed - indexed for MEDLINE]
5.

Dual antiplatelet therapy and antithrombotic treatment in patients with acute coronary syndrome--does everyday medical practice reflects current recommendations? A pilot study.

Pelc-Nowicka A, Bryniarski L, Mirek-Bryniarska E, Zabojszcz M.

Kardiol Pol. 2009 Dec;67(12):1335-41.

PMID:
20054764
[PubMed - indexed for MEDLINE]
Free Article
6.

Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.

Lee HY, Cooke CE, Robertson TA.

J Manag Care Pharm. 2008 Apr;14(3):271-80.

PMID:
18439049
[PubMed - indexed for MEDLINE]
Free Article
7.

Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel.

Chastek B, Riedel AA, Wygant G, Hauch O.

Curr Med Res Opin. 2009 Dec;25(12):2845-52. doi: 10.1185/03007990903333017.

PMID:
19831706
[PubMed - indexed for MEDLINE]
8.

The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.

Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P.

Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000.

PMID:
22974536
[PubMed - indexed for MEDLINE]
9.

One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.

Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A.

J Cardiovasc Med (Hagerstown). 2012 Dec;13(12):783-9. doi: 10.2459/JCM.0b013e3283416b6b.

PMID:
21252697
[PubMed - indexed for MEDLINE]
10.

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.

Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N.

Health Technol Assess. 2009 Jun;13(31):iii-iv, ix-xi, 1-77. doi: 10.3310/hta13310. Review.

PMID:
19573471
[PubMed - indexed for MEDLINE]
Free Article
11.

Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.

Johnston SS, Bell K, Gdovin J, Jing Y, Graham J.

Hosp Pract (1995). 2012 Feb;40(1):15-23. doi: 10.3810/hp.2012.02.944.

PMID:
22406879
[PubMed - indexed for MEDLINE]
12.

Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome.

Philipson TJ, Mozaffari E, Maclean JR.

Am J Manag Care. 2010 Apr;16(4):290-7.

PMID:
20394466
[PubMed - indexed for MEDLINE]
Free Article
13.

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS.

JAMA. 2009 Mar 4;301(9):937-44. doi: 10.1001/jama.2009.261.

PMID:
19258584
[PubMed - indexed for MEDLINE]
14.
15.

Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.

Vermeer NS, Bajorek BV.

J Clin Pharm Ther. 2008 Dec;33(6):591-601. doi: 10.1111/j.1365-2710.2008.00950.x.

PMID:
19138236
[PubMed - indexed for MEDLINE]
16.

Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.

Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW.

Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1043-9. doi: 10.1002/pds.2202. Epub 2011 Aug 8.

PMID:
21823195
[PubMed - indexed for MEDLINE]
17.

Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care.

Fermann GJ, Raja AS, Peterson ED, Roe MT, Hoekstra JW, Milford-Beland S, Diercks DB, Pollack CV Jr, Peacock WF, Summers R, Ohman EM, Gibler WB.

Clin Cardiol. 2009 Sep;32(9):519-25. doi: 10.1002/clc.20629.

PMID:
19743495
[PubMed - indexed for MEDLINE]
18.

Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.

Bonafede M, Jing Y, Gdovin Bergeson J, Liffmann D, Makenbaeva D, Graham J, Deitelzweig SB.

Hosp Pract (1995). 2011 Aug;39(3):16-22. doi: 10.3810/hp.2011.08.575.

PMID:
21881388
[PubMed - indexed for MEDLINE]
19.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
[PubMed - indexed for MEDLINE]
20.

Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.

Zeymer U, James S, Berkenboom G, Mohacsi A, IƱiguez A, Coufal Z, Sartral M, Paget MA, Norrbacka K, Ferrieres J, Bakhai A; APTOR investigators.

Eur J Prev Cardiol. 2013 Apr;20(2):218-28. doi: 10.1177/2047487312437060. Epub 2012 Jan 24.

PMID:
22345684
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk